(Q24798724)

English

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

scientific article

In more languages

Statements

scholarly article

0 references

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762] (English)

0 references

0 references

obsessive-compulsive disorder

1 reference

based on heuristic

inferred from title

3

object named as

Soraya Seedat

0 references

author name string

Paul D Carey

1

0 references

Bavanisha Vythilingum

2

0 references

Jacqueline E Muller

4

0 references

Michael van Ameringen

5

0 references

Dan J Stein

6

0 references

language of work or name

0 references

publication date

2005

0 references

0 references

5

0 references

5

0 references

1

0 references

https://scigraph.springernature.com/pub.10.1186/1471-244x-5-5

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-244x-5-5

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

7 April 2017

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

7 April 2017

https://api.crossref.org/works/10.1186/1471-244X-5-5

22 April 2017

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

7 April 2017

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

7 April 2017

WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 September 2017

A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 September 2017

The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 September 2017

Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

30 May 2018

The Yale-Brown Obsessive Compulsive Scale. II. Validity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

30 May 2018

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

5HT1Dbeta Receptor gene implicated in the pathogenesis of Obsessive-Compulsive Disorder: further evidence from a family-based association study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

Is the 5-HT1DβReceptor Gene Implicated in the Pathogenesis of Obsessive-Compulsive Disorder?

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-5-5

21 January 2018

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 November 2018

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 November 2018

Quetiapine augmentation of sertraline in obsessive-compulsive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 November 2018

Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 November 2018

Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 November 2018

Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 November 2018

Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=547907

28 November 2018

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/15667657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15667657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://pubmed.ncbi.nlm.nih.gov/15667657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapy for obsessive-compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/15667657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-244X-5-5

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-244x-5-5

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24798724&oldid=1969470769"